Hematopoietic Cell Transplantation (HCT) for Non-Hodgkin and other lymphomas
Defines medical necessity criteria, coverage positions (medically necessary vs investigational) and prior authorization requirements for autologous and allogeneic hematopoietic cell transplantation (HCT) across lymphoma subtypes for commercial members. Includes coding guidance and references; outpatient/inpatient prior authorization rules noted.
Clarified coding information.
Annual policy review updated description, summary, and references with policy statements unchanged.
Policy clarified to include authorization requests using Authorization Manager.
Medically necessary policy statement added for hepatosplenic T-cell lymphoma.
Medicare information removed referencing local and national coverage determinations.
Bone marrow harvesting codes were removed and outpatient prior authorization noted.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.